Jenny J. Kim

发表

The unfolding treatment landscape for men with castration-resistant prostate cancer.

E. Antonarakis, S. Denmeade, Jenny J. Kim, 2011, Clinical investigation.

Recent advances in molecularly targeted therapy in advanced renal cell carcinoma

B. Rini, Jenny J. Kim, 2009 .

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

M. Choti, J. Cameron, L. Wood, 2014, Science Translational Medicine.

Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts).

Luigi Marchionni, Gerrit A. Meijer, George J. Netto, 2013 .

Recent Advances in Treatment of Advanced Urothelial Carcinoma

Jenny J. Kim, 2012, Current Urology Reports.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2021, Blood advances.

Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology

S. Hancock, R. Motzer, E. Jonasch, 2015 .

Testicular Cancer, Version 2.2015.

S. Hancock, R. Motzer, E. Jonasch, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

T. Choueiri, N. Agarwal, S. Srinivas, 2014, European urology.

Role of immunotherapy for renal cell cancer in 2011.

M. Carducci, R. Pili, S. George, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Systemic therapy for bladder cancer - a medical oncologist's perspective.

Benjamin A. Teply, Jenny J. Kim, 2014, Journal of solid tumors.

The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation

E. Antonarakis, M. Carducci, M. Eisenberger, 2011, The Prostate.

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

D. Miklos, J. Galon, V. Plaks, 2022, Nature Medicine.

Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

T. Choueiri, M. Fishman, M. Harrison, 2014 .

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

J. Vose, M. Kersten, C. Jacobson, 2021, Blood.

Kidney cancer, version 3.2015.

S. Hancock, R. Motzer, E. Jonasch, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Jenny J. Kim, W. Zhi, 2014, Annals of cancer research.

Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

P. Argani, V. Reuter, J. Hicks, 2012, Human pathology.

Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas

P. Argani, V. Reuter, J. Hicks, 2011, The American journal of surgical pathology.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

B. Rini, R. Dreicer, Jorge A. Garcia, 2012, Cancer.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

T. Choueiri, A. Pantuck, S. Srinivas, 2015, European urology.

Incretin Therapies Do Not Expand &bgr;-Cell Mass or Alter Pancreatic Histology in Young Male Mice

J. Kushner, Changhong Li, A. Cox, 2017, Endocrinology.

Changing landscapes in the treatment of advanced renal cell carcinoma

A. Basu, Jenny J. Kim, H. Emamekhoo, 2016 .

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.

S. Hancock, R. Motzer, E. Jonasch, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

I. Flinn, D. Miklos, C. Jacobson, 2021, Blood.

Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

R. Ganapathi, Jenny J. Kim, S. Vaziri, 2010, Current oncology reports.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J. Burke, A. Eisen, M. Kohli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

I. Flinn, D. Miklos, V. Plaks, 2019, Blood.

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

I. Flinn, D. Miklos, C. Jacobson, 2020 .

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

D. Miklos, C. Jacobson, N. Bartlett, 2020, Blood.

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

J. Vose, M. Kersten, C. Jacobson, 2021, British journal of haematology.

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

R. Houot, M. Kersten, V. Plaks, 2021, British journal of haematology.

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

M. Ross, I. Puzanov, M. Milhem, 2016 .

1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling

D. Miklos, J. Galon, C. Jacobson, 2022, Regular and Young Investigator Award Abstracts.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.

B. Rini, R. Ganapathi, P. Elson, 2010 .

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

C. Jacobson, N. Bartlett, L. Lekakis, 2020 .

Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?

R. Berger, M. Carducci, M. Eisenberger, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

I. Flinn, D. Miklos, C. Jacobson, 2018, Biology of Blood and Marrow Transplantation.

Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

T. Choueiri, N. Agarwal, S. Srinivas, 2014 .

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.

E. Antonarakis, M. Carducci, M. Eisenberger, 2011, European journal of cancer.

Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy.

S. Faraj, S. Bezerra, G. Netto, 2014, Urology.

Kidney cancer, version 2.2014.

S. Hancock, R. Motzer, E. Jonasch, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017 .